Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.55 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | CA7 | P43166 | 2/20 | 0.55 |
| ▸ | CA9 | Q16790 | 2/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7306483 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL11986375 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL16374625 | 1.00 | CA1 (0.55) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4164187 | 0.84 | AHR (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL4158294 | 0.84 | CA1 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL17907419 | 0.82 | ALDH1A1 (0.38) | TDP1MAPK1ALDH1A1NPC1MAPT | |
| SCHEMBL2786401 | 0.82 | CA1 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL5698535 | 0.82 | PTGS2 (0.58) | CA1CA2CA7CA9CA12 | |
| SCHEMBL8779728 | 0.81 | — | — | |
| SCHEMBL12934402 | 0.79 | CA1 (0.61) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115837273-A | Modified metal nano catalyst and preparation method and application thereof | 厦门大学 | 2023-03-24 | — | — | CN | claimed |
| US-4120866-A | REACTING AN AROMATIC COMPOUND WITH A SULFOXIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-17 | — | — | US | claimed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024249254-A2 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-12-05 | — | — | US | disclosed |
| EP-4465982-A2 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2024-11-27 | — | — | EP | disclosed |
| US-11976067-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2024-05-07 | — | — | US | disclosed |
| CN-117486662-A | Method for synthesizing sulfoxide compound by heterogeneous catalysis | 成都理工大学 | 2024-02-02 | — | — | CN | disclosed |
| CN-116870887-A | Titanium dioxide carrier-loaded metal nano catalyst and application thereof | 厦门大学 | 2023-10-13 | — | — | CN | disclosed |
| CN-114657580-B | Electrocatalytic diazonium salt methyl sulfoxide method and methyl sulfoxide derivative | 武汉纺织大学 | 2023-08-29 | — | — | CN | disclosed |
| US-20090196906-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-08-06 | — | — | US | disclosed |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | ALLERGAN, INC. | 2009-04-16 | — | — | US | disclosed |
| US-7393861-B2 | Derivatives of 4-aminopiperidine and their use as a medicament | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2008-07-01 | — | — | US | disclosed |
| US-6727294-B2 | RADIATION TRANSPARENT MOLDING MATERIALS | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2004-04-27 | — | — | US | disclosed |
| US-20010034419-A1 | Radiation transparent molding materials | MITSUBISHI ENGINEERING-PLASTICS CORPORATION (JP) | 2001-10-25 | — | — | US | disclosed |
| US-5506256-A | PREVENTION AND/OR TREATMENT OF DEMENTIA, AMNESIA | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1996-04-09 | — | — | US | disclosed |
| EP-0468469-A2 | Proline derivatives | Japan Tobacco Inc. (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-4889866-A | CARDIOVASCULAR DISEASES, HYPOTENSIVE AGENTS, CONGESTIVE HEART FAILURE | SYNTEX (U.S.A.) INC. (US) | 1989-12-26 | — | — | US | disclosed |
| US-4120866-A | REACTING AN AROMATIC COMPOUND WITH A SULFOXIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1978-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CA1 4256/4885CA2 4457/4885CA7 4776/4885 |
| US-11976067-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, LDLR | CA1 4178/4885CA2 4439/4885CA7 4794/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CA1 4256/4885CA2 4457/4885CA7 4776/4885 |
| US-20090196906-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | CA1 2434/4885CA2 751/4885CA7 1333/4885 |
| US-20240400565-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CA1 4256/4885CA2 4457/4885CA7 4776/4885 |
| US-20090099181-A1 | SULFOXIMINES AS KINASE INHIBITORS | SRC, PTK2B, TYRO3 | CA1 3714/4885CA2 2243/4885CA7 4340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.